SCHEMBL20551887

SCHEMBL20551887

Cc1nc2ccccc2cc1Oc1cnccc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.46
▸ HTT P42858 4/20 0.46
▸ STAT3 P40763 3/20 0.46
▸ MAPT P10636 6/20 0.42
▸ LMNA P02545 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ HPGD P15428 3/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ TLR8 Q9NR97 4/20 0.38
▸ RAB9A P51151 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ CASP1 P29466 1/20 0.36
▸ LCK P06239 1/20 0.36
▸ PTGS1 P23219 2/20 0.35
▸ PTGS2 P35354 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18796132 0.84 SMN1; SMN2 (0.51) SMN1; SMN2HTTSTAT3MAPTLMNA
SCHEMBL18796195 0.75 SMN1; SMN2 (0.54) SMN1; SMN2HTTSTAT3MAPTLMNA
SCHEMBL18796439 0.75 HTT (0.54) SMN1; SMN2HTTSTAT3MAPTLMNA
SCHEMBL29207072 0.72 HTT (0.59) SMN1; SMN2HTTSTAT3MAPTLMNA
SCHEMBL18796297 0.72 MAPT (0.48) SMN1; SMN2HTTSTAT3MAPTLMNA
SCHEMBL18796155 0.72 SMN1; SMN2 (0.51) SMN1; SMN2HTTSTAT3MAPTLMNA
SCHEMBL18796216 0.72 HTT (0.51) SMN1; SMN2HTTSTAT3MAPTLMNA
SCHEMBL18796468 0.71 SMN1; SMN2 (0.50) SMN1; SMN2HTTSTAT3MAPTLMNA
SCHEMBL5117776 0.70 TLR8 (0.65) SMN1; SMN2HTTSTAT3MAPTLMNA
SCHEMBL6849143 0.69 ALDH1A1 (0.59) SMN1; SMN2HTTSTAT3MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200231607-A1 TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES BAYER AKTIENGESELLSCHAFT (DE) 2020-07-23 — — US disclosed
EP-3618632-A1 TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES Bayer Aktiengesellschaft (DE) 2020-03-11 — — EP disclosed
WO-2018202706-A1 TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES BAYER AKTIENGESELLSCHAFT (DE) 2018-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200231607-A1 TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES PIK3C3, ERG28, DDT SMN1; SMN2 4327/4885HTT 3813/4885STAT3 4621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback